
Nikos Stathopoulos
Chairman, Europe, Member of the Management Committee
Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.
In July 2021, BC Partners announced the sale of Pharmathen to Partners Group.
Chairman, Europe, Member of the Management Committee
Partner, Private Equity, Co-head of Healthcare
Managing Director, Private Equity
LONDON, July 19, 2021 – International investment firm BC Partners today announced the sale of Pharmathen (“the Company”), a leading…
London, 3 June 2015 – Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached…
At BC, we provide our portfolio companies with the access and expertise to scale into leading global businesses. We are a partner for growth.